You are here

  • Home
  • Archive
  • Volume 23, Issue Suppl 1
  • PS-014 Safety analysis of ledipasvir/sofosbuvir, with or without ribavirin, in patients with chronic hepatitis C virus infection: Adverse events and drug interactions

Article metrics

Article menu
Download PDFPDF
Patient safety and risk management
PS-014 Safety analysis of ledipasvir/sofosbuvir, with or without ribavirin, in patients with chronic hepatitis C virus infection: Adverse events and drug interactions

 

Online download statistics by month:

Online download statistics by month: March 2016 to March 2024

AbstractFullPdf
Mar 2016100
Apr 2016102
May 2016200
Jun 2016500
Jul 2016302
Aug 2016100
Sep 2016500
Oct 2016600
Nov 2016300
Dec 2016100
Jan 2017200
Feb 20173601
Mar 20171100
Apr 20171001
May 20171200
Jun 2017602
Jul 2017700
Aug 2017600
Sep 20173400
Oct 20172200
Nov 20171600
Dec 20171600
Jan 20184600
Feb 20182400
Mar 20185400
Apr 20184000
May 20185000
Jun 20182000
Jul 20181000
Aug 20181200
Sep 2018800
Oct 20181400
Nov 20181800
Dec 20181600
Jan 20191400
Feb 2019800
Apr 2019401
May 2019200
Jun 2019200
Jul 2019200
Aug 2019800
Sep 20191200
Oct 20191600
Nov 2019400
Dec 2019802
Jan 20201200
Feb 20201400
Mar 20201000
Apr 20201000
May 2020600
Jun 20201400
Jul 2020600
Aug 2020800
Sep 20201000
Oct 20204801
Nov 20204700
Dec 20201600
Jan 20211200
Feb 20211400
Mar 2021400
Apr 2021400
Oct 2021402
Nov 20211600
Dec 20211400
Jan 20221200
Feb 20221201
Mar 20221200
Apr 2022800
May 20221000
Jun 2022400
Jul 2022800
Aug 20221900
Sep 20221800
Oct 2022400
Nov 2022800
Dec 20221600
Jan 20231000
Feb 20231201
Mar 2023400
May 2023200
Jul 2023600
Aug 20231000
Sep 20232000
Oct 20231600
Nov 2023400
Dec 20232200
Jan 20241200
Feb 20242800
Mar 20241800
Total1162016